Influence of Vanin-1 and Catalytic Products in Liver during Normal and Oxidative Stress Conditions

Current Medicinal Chemistry

Volumn 22, Issue 20, 2015, Pages 2407-2416

  Ferreira, Daniel W ^a   Naquet, Philippe ^b   Manautou, Jose E ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

coenzyme A.; cystamine; cysteamine; hepatoxicity; liver; mitochondria; oxidative stress; pantetheinase; Vanin

Indexed keywords

CARBON TETRACHLORIDE; CYSTAMINE; GALACTOSAMINE; MEMBRANE PROTEIN; MERCAPTAMINE; PANTETHEINE; PARACETAMOL; UNCLASSIFIED DRUG; VANIN 1; AMIDASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PANTETHEINASE;

ANTIOXIDANT ACTIVITY; ARTICLE; BIOSYNTHESIS; CATALYST; CELL SURFACE; CELL SURVIVAL; COVALENT BOND; DISULFIDE BOND; ENZYME MECHANISM; HOMEOSTASIS; IMMUNOCOMPETENT CELL; IN VIVO STUDY; LIVER PROTECTION; LIVER TOXICITY; METABOLITE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN INTERACTION; TRANSCRIPTION REGULATION; ANIMAL; BIOCATALYSIS; ENZYMOLOGY; HUMAN; LIVER; METABOLISM;

AMIDOHYDROLASES; ANIMALS; BIOCATALYSIS; GPI-LINKED PROTEINS; HUMANS; LIVER; OXIDATIVE STRESS;

EID: 84938629859     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986732220150722124307     Document Type: Article

References (100)

1. Rommelaere, S., et al., PPARalpha regulates the production of serum Vanin-1 by liver. FEBS Lett, 2013. 587(22): p. 3742-8
2. Pitari, G., et al., Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett, 2000. 483(2-3): p. 149-54
3. Martin, F., et al., Vanin-1(-/-) mice show decreased NSAID-and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J Clin Invest, 2004. 113(4): p. 591-7
4. Paulick, M.G. And C.R. Bertozzi, The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry, 2008. 47(27): p. 6991-7000
5. Maeda, Y. And T. Kinoshita, Structural remodeling, trafficking and functions of glycosylphosphatidylinositol-anchored proteins. Progress in lipid research, 2011. 50(4): p. 411-24
6. Ait-Slimane, T., et al., Basolateral internalization of GPI-anchored proteins occurs via a clathrin-independent flotillin-dependent pathway in polarized hepatic cells. Mol Biol Cell, 2009. 20(17): p. 3792-800
7. Jansen, P.A., et al., Expression of the vanin gene family in normal and inflamed human skin: induction by proinflammatory cytokines. The Journal of investigative dermatology, 2009. 129(9): p. 2167-74
8. Su, A.I., et al., A gene atlas of the mouse and human proteinencoding transcriptomes. Proceedings of the National Academy of Sciences of the United States of America, 2004. 101(16): p. 6062-7
9. Motomura, W., et al., Analysis of vanin-1 upregulation and lipid accumulation in hepatocytes in response to a high-fat diet and free fatty acids. J Clin Biochem Nutr, 2012. 51(3): p. 163-9
10. Moffit, J.S., et al., Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate. Toxicology and applied pharmacology, 2007. 222(2): p. 169-79
11. Yamazaki, K., J. Kuromitsu, and I. Tanaka, Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor alpha agonists. Biochemical and biophysical research communications, 2002. 290(3): p. 1114-22
12. Wong, J.S. And S.S. Gill, Gene expression changes induced in mouse liver by di(2-ethylhexyl) phthalate. Toxicology and applied pharmacology, 2002. 185(3): p. 180-96
13. Daugherty, M., et al., Complete reconstitution of the human coenzyme A biosynthetic pathway via comparative genomics. The Journal of biological chemistry, 2002. 277(24): p. 21431-9
14. Jansen, P.A., et al., Discovery of Small Molecule Vanin Inhibitors: New Tools To Study Metabolism and Disease. ACS Chem Biol, 2013
15. Pitari, G., et al., Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS letters, 2000. 483(2-3): p. 149-54
16. Dominy, J.E., Jr., et al., Discovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase. The Journal of biological chemistry, 2007. 282(35): p. 25189-98
17. Cavallini, D., et al., The enzymatic oxidation of cysteamine to hypotaurine. Purification and properties of the enzyme. J Biol Chem, 1966. 241(13): p. 3189-96
18. Sumizu, K., Oxidation of hypotaurine in rat liver. Biochimica et biophysica acta, 1962. 63: p. 210-2
19. Oja, S.S. And P. Kontro, Oxidation of hypotaurine in vitro by mouse liver and brain tissues. Biochimica et biophysica acta, 1981. 677(3-4): p. 350-7
20. Stipanuk, M.H., et al., Mammalian cysteine metabolism: new insights into regulation of cysteine metabolism. J Nutr, 2006. 136(6 Suppl): p. 1652S-1659S.
21. Duffel, M.W., D.J. Logan, and D.M. Ziegler, Cysteamine and cystamine. Methods in enzymology, 1987. 143: p. 149-54
22. Nurminskaya, M.V. And A.M. Belkin, Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol, 2012. 294: p. 1-97
23. Miyazaki, T. And Y. Matsuzaki, Taurine and liver diseases: a focus on the heterogeneous protective properties of taurine. Amino acids, 2012
24. van Stijn, M.F., et al., Human taurine metabolism: fluxes and fractional extraction rates of the gut, liver, and kidneys. Metabolism: clinical and experimental, 2012. 61(7): p. 1036-40
25. Tachibana, K., et al., Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl Recept, 2005. 3: p. 3
26. Rakhshandehroo, M., et al., Peroxisome proliferator-activated receptor alpha target genes. PPAR Res, 2010. 2010
27. Berruyer, C., et al., Vanin-1-/-mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol Cell Biol, 2004. 24(16): p. 7214-24
28. Denk, G.U., et al., A comparison of gene expression in mouse liver and kidney in obstructive cholestasis utilizing high-density oligonucleotide microarray technology. World journal of gastroenterology: WJG, 2006. 12(16): p. 2536-48
29. Chai, J., et al., Elevated hepatic multidrug resistance-associated protein 3/ATP-binding cassette subfamily C 3 expression in human obstructive cholestasis is mediated through tumor necrosis factor alpha and c-Jun NH2-terminal kinase/stress-activated protein kinase-signaling pathway. Hepatology, 2012. 55(5): p. 1485-94
30. Sato, W., et al., Hepatic gene expression in hepatocyte-specific Pten deficient mice showing steatohepatitis without ethanol challenge. Hepatol Res, 2006. 34(4): p. 256-65
31. Yu, S., et al., Identification of promethin and PGLP as two novel up-regulated genes in PPARgamma1-induced adipogenic mouse liver. Biochimie, 2004. 86(11): p. 743-61
32. Guillen, N., et al., Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiol Genomics, 2009. 37(3): p. 187-98
33. Rao, D.V., et al., Induction of sperm head abnormalities by incorporated radionuclides: dependence on subcellular distribution, type of radiation, dose rate, and presence of radioprotectors. Radiat Res, 1991. 125(1): p. 89-97
34. Harapanhalli, R.S., et al., [35S]cysteamine: facile synthesis, in vivo biokinetics, and subcellular distribution. Nucl Med Biol, 1993. 20(1): p. 117-24
35. Winterbourn, C.C. And D. Metodiewa, Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic Biol Med, 1999. 27(3-4): p. 322-8
36. Skrede, S. And B.O. Christophersen, Effects of cystamine and cysteamine on the peroxidation of lipids and the release of proteins from mitochondria. Biochem J, 1966. 101(1): p. 37-41
37. Christophersen, B.O., The inhibitory effect of reduced glutathione on the lipid peroxidation of the microsomal fraction and mitochondria. Biochem J, 1968. 106(2): p. 515-22
38. Castro, J.A., et al., Studies on the mechanism of cystamine prevention of several liver structural and biochemical alterations caused by carbon tetrachloride. Toxicology and applied pharmacology, 1973. 24(1): p. 1-19
39. Ferreyra, E.C., et al., Treatment of carbon tetrachloride-induced liver necrosis with chemical compounds. Toxicology and applied pharmacology, 1977. 42(3): p. 513-21
40. Nagiel-Ostaszewski, I. And C.A. Lau-Cam, Protection by pantethine, pantothenic acid and cystamine against carbon tetrachloride-induced hepatotoxicity in the rat. Res Commun Chem Pathol Pharmacol, 1990. 67(2): p. 289-92
41. MacDonald, J.R., A.J. Gandolfi, and I.G. Sipes, Cystamine modulation of galactosamine-induced hepatotoxicity. Toxicology and applied pharmacology, 1984. 73(3): p. 551-8
42. MacDonald, J.R., K.J. Thayer, and C. White, Inhibition of galactosamine cytotoxicity in an in vivo/in vitro hepatocellular toxicity model. Toxicology and applied pharmacology, 1987. 89(2): p. 269-77
43. Prescott, L.F., et al., Successful treatment of severe paracetamol overdosage with cysteamine. Lancet, 1974. 1(7858): p. 588-92
44. Prescott, L.F., et al., Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning. Lancet, 1976. 2(7977): p. 109-13
45. Miners, J.O., R. Drew, and D.J. Birkett, Mechanism of action of paracetamol protective agents in mice in vivo. Biochem Pharmacol, 1984. 33(19): p. 2995-3000
46. Peterson, T.C., M.R. Peterson, and C.N. Williams, The role of heme oxygenase and aryl hydrocarbon hydroxylase in the protection by cysteamine from acetaminophen hepatotoxicity. Toxicol Appl Pharmacol, 1989. 97(3): p. 430-9
47. Peterson, T.C. And I.R. Brown, Cysteamine in combination with Nacetylcysteine prevents acetaminophen-induced hepatotoxicity. Can J Physiol Pharmacol, 1992. 70(1): p. 20-8
48. Miller, M.G. And D.J. Jollow, Acetaminophen hepatotoxicity: studies on the mechanism of cysteamine protection. Toxicol Appl Pharmacol, 1986. 83(1): p. 115-25
49. Tynes, R.E. And E. Hodgson, Catalytic activity and substrate specificity of the flavin-containing monooxygenase in microsomal systems: characterization of the hepatic, pulmonary and renal enzymes of the mouse, rabbit, and rat. Arch Biochem Biophys, 1985. 240(1): p. 77-93
50. Suh, J.K., et al., Redox regulation of yeast flavin-containing monooxygenase. Arch Biochem Biophys, 2000. 381(2): p. 317-22
51. Townsend, D.M., S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. Mol Interv, 2007. 7(6): p. 313-24
52. Iyer, S.S., et al., Cysteine redox potential determines proinflammatory IL-1beta levels. PLoS One, 2009. 4(3): p. e5017
53. Bulaj, G., T. Kortemme, and D.P. Goldenberg, Ionization-reactivity relationships for cysteine thiols in polypeptides. Biochemistry, 1998. 37(25): p. 8965-72
54. O'Brian, C.A. And F. Chu, Post-translational disulfide modifications in cell signaling-role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission. Free Radic Res, 2005. 39(5): p. 471-80
55. Miller, R.M., et al., Phosphorylase and creatine kinase modification by thiol-disulfide exchange and by xanthine oxidaseinitiated S-thiolation. Arch Biochem Biophys, 1990. 276(2): p. 355-63
56. Cappiello, M., et al., Specifically targeted modification of human aldose reductase by physiological disulfides. J Biol Chem, 1996. 271(52): p. 33539-44
57. Lesort, M., et al., Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders. J Biol Chem, 2003. 278(6): p. 3825-30
58. Mallis, R.J., J.E. Buss, and J.A. Thomas, Oxidative modification of H-ras: S-thiolation and S-nitrosylation of reactive cysteines. Biochem J, 2001. 355(Pt 1): p. 145-53
59. Hsu, T.C., et al., Beneficial effects of treatment with transglutaminase inhibitor cystamine on macrophage response in NZB/W F1 mice. Exp Biol Med (Maywood), 2007. 232(2): p. 195-203
60. Ozaki, T., et al., Effect of thiol-containing molecule cysteamine on the induction of inducible nitric oxide synthase in hepatocytes. JPEN J Parenter Enteral Nutr, 2007. 31(5): p. 366-71; discussion 371-2
61. Darby, N.J., R.B. Freedman, and T.E. Creighton, Dissecting the mechanism of protein disulfide isomerase: catalysis of disulfide bond formation in a model peptide. Biochemistry, 1994. 33(25): p. 7937-47
62. Wang, G.Z., X.Y. Dong, and Y. Sun, Acyl cystamine: smallmolecular foldase mimics accelerating oxidative refolding of disulfide-containing proteins. Biotechnol Prog, 2011. 27(2): p. 377-85
63. Stuber, D., et al., Alignment of disulfide bonds of the extracellular domain of the interferon gamma receptor and investigation of their role in biological activity. Biochemistry, 1993. 32(9): p. 2423-30
64. Curbo, S., et al., Regulation of interleukin-4 signaling by extracellular reduction of intramolecular disulfides. Biochemical and biophysical research communications, 2009. 390(4): p. 1272-7
65. Yang, H., et al., Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med, 2012. 18: p. 250-9
66. Yan, B. And J.W. Smith, Mechanism of integrin activation by disulfide bond reduction. Biochemistry, 2001. 40(30): p. 8861-7
67. Lebo, R.V. And N.M. Kredich, Inactivation of human gammaglutamylcysteine synthetase by cystamine. Demonstration and quantification of enzyme-ligand complexes. The Journal of biological chemistry, 1978. 253(8): p. 2615-23
68. Berruyer, C., et al., Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med, 2006. 203(13): p. 2817-27
69. Pouyet, L., et al., Epithelial vanin-1 controls inflammation-driven carcinogenesis in the colitis-associated colon cancer model. Inflamm Bowel Dis, 2010. 16(1): p. 96-104
70. Roisin-Bouffay, C., et al., Mouse vanin-1 is cytoprotective for islet beta cells and regulates the development of type 1 diabetes. Diabetologia, 2008. 51(7): p. 1192-201
71. Aurrand-Lions, M., et al., Vanin-1, a novel GPI-linked perivascular molecule involved in thymus homing. Immunity, 1996. 5(5): p. 391-405
72. Zhu, X. And R.S. Cooper, Admixture mapping provides evidence of association of the VNN1 gene with hypertension. PLoS One, 2007. 2(11): p. e1244
73. Fava, C., et al., Vanin-1 T26I polymorphism, hypertension and cardiovascular events in two large urban-based prospective studies in Swedes. Nutr Metab Cardiovasc Dis, 2013. 23(1): p. 53-60
74. Issels, R.D., et al., Enhancement of cysteamine cytotoxicity by hyperthermia and its modification by catalase and superoxide dismutase in Chinese hamster ovary cells. Cancer Res, 1984. 44(9): p. 3911-5
75. Khomenko, T., et al., Effect of cysteamine on redox-sensitive thiolcontaining proteins in the duodenal mucosa. Biochemical and biophysical research communications, 2003. 309(4): p. 910-6
76. Meghari, S., et al., Vanin-1 controls granuloma formation and macrophage polarization in Coxiella burnetii infection. Eur J Immunol, 2007. 37(1): p. 24-32
77. Dangaj, D., et al., Mannose receptor (MR) engagement by mesothelin GPI anchor polarizes tumor-associated macrophages and is blocked by anti-MR human recombinant antibody. PLoS One, 2011. 6(12): p. e28386
78. Choi, S.Y., et al., Cardiolipin deficiency releases cytochrome c from the inner mitochondrial membrane and accelerates stimulielicited apoptosis. Cell Death Differ, 2007. 14(3): p. 597-606
79. Houtkooper, R.H. And F.M. Vaz, Cardiolipin, the heart of mitochondrial metabolism. Cell Mol Life Sci, 2008. 65(16): p. 2493-506
80. Sakamoto, T., et al., Deficiency of cardiolipin synthase causes abnormal mitochondrial function and morphology in germ cells of Caenorhabditis elegans. J Biol Chem, 2012. 287(7): p. 4590-601
81. Jiang, F., et al., Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem, 2000. 275(29): p. 22387-94
82. Mao, Z., Y.S. Choo, and M. Lesort, Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur J Neurosci, 2006. 23(7): p. 1701-10
83. Gibrat, C. And F. Cicchetti, Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry, 2011. 35(2): p. 380-9
84. Jeitner, T.M., et al., Mechanism for the inhibition of transglutaminase 2 by cystamine. Biochem Pharmacol, 2005. 69(6): p. 961-70
85. Lorand, L. And S.M. Conrad, Transglutaminases. Mol Cell Biochem, 1984. 58(1-2): p. 9-35
86. Malorni, W., et al., The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrialdependent apoptosis. Cell Death Differ, 2009. 16(11): p. 1480-92
87. Park, D., S.S. Choi, and K.S. Ha, Transglutaminase 2: a multifunctional protein in multiple subcellular compartments. Amino Acids, 2010. 39(3): p. 619-31
88. Krasnikov, B.F., et al., Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria. Biochemistry, 2005. 44(21): p. 7830-43
89. Ruan, Q., R.A. Quintanilla, and G.V. Johnson, Type 2 transglutaminase differentially modulates striatal cell death in the presence of wild type or mutant huntingtin. J Neurochem, 2007. 102(1): p. 25-36
90. Kim, S.Y., et al., Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain. Neurochem Res, 2005. 30(10): p. 1245-55
91. Cooper, A.J., et al., Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alphaketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. Proc Natl Acad Sci U S A, 1997. 94(23): p. 12604-9
92. Bailey, C.D. And G.V. Johnson, Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms. J Neurochem, 2005. 92(1): p. 83-92
93. Mastroberardino, P.G., et al., 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ, 2002. 9(9): p. 873-80
94. Karpuj, M.V., et al., Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med, 2002. 8(2): p. 143-9
95. Borrell-Pages, M., et al., Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest, 2006. 116(5): p. 1410-24
96. Stack, E.C., et al., Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim Biophys Acta, 2008. 1782(3): p. 151-62
97. Qiu, J.F., et al., Cystamine ameliorates liver fibrosis induced by carbon tetrachloride via inhibition of tissue transglutaminase. World J Gastroenterol, 2007. 13(32): p. 4328-32
98. Hurd, T.R., et al., Complex I within oxidatively stressed bovine heart mitochondria is glutathionylated on Cys-531 and Cys-704 of the 75-kDa subunit: potential role of CYS residues in decreasing oxidative damage. J Biol Chem, 2008. 283(36): p. 24801-15
99. Mailloux, R.J., et al., Glutathionylation state of uncoupling protein-2 and the control of glucose-stimulated insulin secretion. J Biol Chem, 2012. 287(47): p. 39673-85
100. Delavoie, F., et al., In vivo and in vitro peripheral-type benzodiazepine receptor polymerization: functional significance in drug ligand and cholesterol binding. Biochemistry, 2003. 42(15): p. 4506-19.